Randomized Trial of Allopurinol in the Prevention of Calcium Oxalate Calculi

New England Journal of Medicine

Volumn 315, Issue 22, 1986, Pages 1386-1389

  Ettinger, Bruce ^a,b,c   Tang, Anne ^a,b,c   Citron, John T ^a,b,c   Livermore, Barbara ^a,b,c   Williams, Thomas ^a,b,c  

^a KAISER PERMANENTE   (United States)

^b Walnut Creek ^*  (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CALCIUM OXALATE; PLACEBO;

BLOOD AND HEMOPOIETIC SYSTEM; DRUG EFFICACY; DRUG THERAPY; HUMAN; HYPERURICOSURIA; KIDNEY; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PREVENTION; PRIORITY JOURNAL; THERAPY;

EID: 0022908826     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198611273152204     Document Type: Article

References (28)

1. Hiatt RA, Dales LG, Friedman GD, Hunkeler EM. Frequency of uroiithiasis in a prepaid medical care program. Am J Epidemiol 1982; 115: 255–65.
2. Ahlstrand C, Tiselius H-G. Renal stone disease in a Swedish district during one year. Scand J Urol Nephrol 1981; 15: 143–6.
3. Johnson CM, Wilson DM, O'Fallon WM, Malek RS, Kurland LT. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 1979; 16: 624–31.
4. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med 1977; 87: 404–10.
5. Maschio G, Tessitore N, D'Angelo A, et al. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol. Am J Med 1981; 71: 623–6.
6. Pak CYC. Medical management of nephrolithiasis. J Urol 1982; 128: 1157–64.
7. Coe FL, Raisen L. Allopurinol treatment of uric-acid disorders in calcium-stone formers. Lancet 1973; 1: 129–31.
8. Coe FL, Kavalach AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 1974; 291:1344–50.
9. Miano L, Petta S, Paradiso Galatioto G, Goldoni S, Tubaro A. A placebo controlled double-blind study of allopurinol in severe recurrent idiopathic renal lithiasis: preliminary results. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:521–4.
10. Recurrence of renal stones. Lancet 1980; 1: 187–8.
11. Smith MJV. Placebo versus allopurinol for renal calculi. J Urol 1977; 117: 690–2.
12. Scott R, Mathieson A, McLelland A. The reduction in stone recurrence and oxalate excretion by allopurinol. In: Rose GA, Robertson WG, Watts RWE, eds. Oxalate in human biochemistry and clinical pathology: proceedings of an international meeting in London, Oct. 26–27, 1979. London: Wellcome Foundation, 1979:191–7.
13. Wilson DR, Strauss AL, Manuel MA. Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urol Res 1984; 12: 39–40. abstract.
14. Robertson WG, Peacock M, Selby PL, et al. A multicentre trial to evaluate three treatments for recurrent idiopathic calcium stone disease — a preliminary report. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:545–8.
15. Marangella M, Tricerri A, Ronzani M, et al. The relationship between clinical outcome and urine biochemistry during various forms of therapy for idiopathic calcium stone disease. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:561–4.
16. Fellström B, Backman U, Danielson BG, et al. Allopurinol treatment of renal calcium stone disease. Br J Urol 1985; 57: 375–9.
17. Ulshöfer B, Zenke J, Achilles W, Rodeck G. The effect of long-term treatment with allopurinol on stone recurrence in calcium urolithiasis. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:517–9.
18. Sidney S, Friedman GD, Siegelaub AB. Thinness and mortality. Am J Public Health (in press).
19. Finlayson B, Newman RC, Hunter PT. The role of urate and allopurinol in stone disease: a review. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:499–503.
20. Citron J, Tang A, Ettinger B. A model for predicting stone recurrences. Urol Res 1984; 12: 97. abstract.
21. Ettinger B. Recurrence of nephrolithiasis: a six-year prospective study. Am J Med 1979; 67: 245–8.
22. Brocks P. Dahl C, Wolf H, Transbøl I. Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 1981; 2: 124–5.
23. Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH. The stone clinic effect in patients with idiopathic calcium urolithiasis. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:453–6.
24. Ettinger B, Citron JT, Tang A, Livermore B. Prophylaxis of calcium oxalate stones: clinical trials of allopurinol, magnesium hydroxide and chlorthalidone. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:549–52.
25. Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 1982; 128: 903–7.
26. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis: a double blind study in general practice. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:475–8.
27. Joost J, Putz A. Calcium oxalate stone formers five years later. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, eds. Urolithiasis and related clinical research. New York: Plenum Press, 1985:557–60.
28. Young JL Jr, Boswell RB, Nies AS. Severe allopurinol hypersensitivity: association with thiazides and prior renal compromise. Arch Intern Med 1974; 134: 553–8.